Allos Therapeutics Inc - Current report filing (8-K)
15 Maio 2008 - 7:12AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): May 15, 2008
ALLOS
THERAPEUTICS, INC.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
|
|
|
|
|
11080
CirclePoint Road, Suite 200
|
|
|
Westminster,
Colorado
|
|
80020
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
|
|
|
|
|
Registrants
telephone number, including area code:
(303)
426-6262
|
|
|
|
|
|
Not
applicable
|
(Former name or
former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On May 15, 2008,
Allos Therapeutics, Inc., a Delaware corporation
(the Company), issued a press release
reporting interim response and safety data from the Companys pivotal
Phase 2 PROPEL trial of PDX (pralatrexate) in patients with relapsed or
refractory peripheral T-cell lymphoma. The press release is attached hereto as Exhibit 99.1
and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1
|
Press Release, dated
May 15, 2008, entitled Allos
Therapeutics Reports Interim Response and Safety Data from Pivotal Phase 2
PROPEL Trial.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Dated: May 15, 2008
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President,
General Counsel and Secretary
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated
May 15, 2008, entitled Allos
Therapeutics Reports Interim Response and Safety Data from Pivotal Phase 2
PROPEL Trial.
|
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics Inc